Risk Factors of Cetuximab-Induced Hypomagnesemia and the Effect of Magnesium Prophylaxis in Patients with Head and Neck Cancer: A Retrospective Study-Reference-Cited by-同舟云学术

Risk Factors of Cetuximab-Induced Hypomagnesemia and the Effect of Magnesium Prophylaxis in Patients with Head and Neck Cancer: A Retrospective Study

Published:2024-03-29 Issue:3 Volume:47 Page:732-738
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Matsukane Ryosuke¹,Isshiki Risa²,Suetsugu Kimitaka¹,Minami Haruna¹,Hata Kojiro¹,Matsuo Mioko³,Egashira Nobuaki¹²,Hirota Takeshi¹²,Nakagawa Takashi³,Ieiri Ichiro¹²

Affiliation:

1. Department of Pharmacy, Kyushu University Hospital

2. Department of Clinical Pharmacology and Biopharmaceutics, Graduated School of Pharmaceutical Sciences, Kyushu University

3. Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University

Publisher

Pharmaceutical Society of Japan

Link

https://www.jstage.jst.go.jp/article/bpb/47/3/47_b23-00714/_pdf

Reference22 articles.

1. 1) Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res., 5, 203–220 (2007).

2. 2) Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H-R, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med., 359, 1116–1127 (2008).

3. 3) Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann. Oncol., 23, 1016–1022 (2012).

4. 4) Enokida T, Okano S, Fujisawa T, Ueda Y, Uozumi S, Tahara M. Paclitaxel plus cetuximab as 1st line chemotherapy in platinum-based chemoradiotherapy-refractory patients with squamous cell carcinoma of the head and neck. Front. Oncol., 8, 339 (2018).

5. 5) Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst., 97, 1221–1224 (2005).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of serum magnesium levels for prognosis in patients with non-small cell lung cancer undergoing EGFR-TKI therapy;Open Life Sciences;2024-01-01